ABOUT
Welcome to the 2nd Covalent Drug Discovery & Development Summit
As covalent inhibitors with improved safety and potency progress from the bench to the clinic, the 2nd Covalent Drug Discovery & Development Summit returns with 3 days jam-packed with industry insights to address your most prevalent pain points, such as:
 |
Leveraging lysine-, tyrosine- and histidine-based covalency across the disease spectrum to develop best- and first-in class therapies against known and previously undruggable targets |
|
Rationally designing covalent heterobifunction and monovalent small molecules displaying alternative mechanisms of action |
|
Minimizing off-target toxicity of your covalent drugs while building in high target specificity in oncology and chronic conditions |
|
Accelerating your chemical biology enabled covalent drug discovery from hit to clinic against transcription factors, E3 ligases, immunology targets and beyond |
Uniting 100+ Heads, Directors and VPs of Proteomics, Medicinal Chemistry, Chemical Biology, Discovery Biology and Pharmacology with KOLs of academia, this meeting is your unrivalled opportunity to foster critical conversations and navigate the cutting-edge platforms at the cusp of expanding the druggable proteome with new covalent chemistry.
5 Reasons Not to Miss Out in 2024:
Overcome challenges in balancing reactivity and sensitivity with advanced and scalable screening cascades to rationally develop covalent handles and streamline the triage of tractable compounds with insights from Genentech, Scorpion Therapeutics & Covant Therapeutics
Supercharge the discovery of highly selective covalent drugs by advancing chemoproteomic platforms and novel probes to assess pharmacology and mitigate their highly contested off-target safety risks with input from Biogen, Nexo Therapeutics & Lundbeck
Propel the development of novel warheads for covalent screening of histidine, tyrosine and lysine residues to expand the druggable proteome and target novel binding pockets with insights from HYKU Biomedicines, Armida Labs & Bayer
Unlock novel disease indications stemming immunology, inflammatory and CNS conditions by progressing the identification and validation of covalent drugs for hard-to-drug targets beyond KRAS G12C, BTK and EGFR with drug discovery and clinical insights from Novartis, Taiho Pharmaceutical & Covant Therapeutics
Advance covalency beyond irreversible inhibition by tapping into the advancing paradigm of covalent PROTACs, monovalent degraders and highly selective biologics, charting the course for first-in-class drugs with insights from Harvard, Pfizer & Amgen